Drug Safety

, Volume 30, Issue 3, pp 247–264 | Cite as

Evaluating the Postmarketing Experience of Risperidone Use During Pregnancy

Pregnancy and Neonatal Outcomes
  • Danielle Coppola
  • Leo J. Russo
  • Robert F. KwartaJr
  • Ruana Varughese
  • Juergen Schmider
Original Research Article


Background: A significant number of women of childbearing age have schizophrenia or other psychoses. This means that there is a considerable risk of in utero exposure to risperidone due to maternal use.

Objective: To determine whether in utero exposure to the atypical antipsychotic risperidone is associated with poor pregnancy and fetal/neonatal outcomes.

Methods: A search of the Benefit Risk Management Worldwide Safety database, using a selection of preferred terms from the Medical Dictionary of Regulatory Activities, was performed to identify all cases of pregnancy or fetal/neonatal outcomes reported in association with risperidone treatment from its first market launch (international birth date, 1 June 1993) to 31 December 2004. The main measures were the patterns and reporting rates of pregnancy (stillbirth and spontaneous and induced abortion) and fetal/neonatal outcomes (congenital abnormalities, perinatal syndromes and withdrawal symptoms) for women administered risperidone during pregnancy.

Results: Overall, 713 pregnancies were identified in women who were receiving risperidone. Data were considered prospective in 516 of these, and retrospective in the remaining 197 cases. The majority of the known adverse pregnancy and fetal/neonatal outcomes were retrospectively reported. Of the 68 prospectively reported pregnancies with a known outcome, organ malformations and spontaneous abortions occurred 3.8% and 16.9% (when the 15 induced abortions were excluded from the denominator, as they were predominantly undertaken for nonmedical reasons), respectively, a finding consistent with background rates of the general population. There were 12 retrospectively reported pregnancies involving major organ malformations, the most frequently reported of which affected the heart, brain, lip and/or palate. There were 37 retrospectively reported pregnancies involving perinatal syndromes, of which 21 cases involved behavioural or motor disorders. In particular, there was a cluster of cases reporting tremor, jitteriness, irritability, feeding problems and somnolence, which may represent a withdrawal-emergent syndrome.

Conclusion: This comprehensive review of the Benefit Risk Management Worldwide Safety database for case reports of risperidone exposure during pregnancy represents the largest ever published dataset documenting pregnancy outcomes for women taking the atypical antipsychotic risperidone. It indicates that in utero exposure to risperidone does not appear to increase the risk of spontaneous abortions, structural malformations and fetal teratogenic risk above that of the general population. Self-limited extrapyramidal effects in neonates were observed after maternal exposure to risperidone during the third trimester of pregnancy. Risperidone should only be used during pregnancy if the benefits outweigh the potential risks.



All authors are employees of Benefit Risk Management, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC, Titusville, New Jersey, USA.

The authors would like to thank Frances Gambling, Medicus International, for her editorial assistance.


  1. 1.
    Leung A, Chue P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr Scand Suppl. 2000; 401: 3–38PubMedCrossRefGoogle Scholar
  2. 2.
    Howard LM, Kumar C, Leese M, et al. The general fertility rate in women with psychotic disorders. Am J Psychiatry 2002; 159: 991–7PubMedCrossRefGoogle Scholar
  3. 3.
    Calabrese JR, Gulledge AD. Psychotropics during pregnancy and lactation: a review. Psychosomatics 1985 May; 26(5): 413–6PubMedCrossRefGoogle Scholar
  4. 4.
    Mortola JF. The use of psychotropic agents in pregnancy and lactation. Psychiatr Clin North Am 1989 Mar; 12(1): 69–87PubMedGoogle Scholar
  5. 5.
    Miller LJ. Clinical strategies for the use of psychotropic drugs during pregnancy. Psychiatr Med 1991; 9(2): 275–98PubMedGoogle Scholar
  6. 6.
    Cohen LS. Psychotropic drug use in pregnancy. Hosp Community Psychiatry 1989 Jun; 40(6): 566–7PubMedGoogle Scholar
  7. 7.
    Thiels C, Steinhausen HC. Pharmacotherapy of psychiatric disorder in pregnancy and during breastfeeding: a review. Pharmacopsychiatry 1987 Jul; 20(4): 133–46PubMedCrossRefGoogle Scholar
  8. 8.
    Goldberg HL. Psychotropic drugs in pregnancy and lactation. Int J Psychiatry Med 1994; 24(2): 129–47PubMedCrossRefGoogle Scholar
  9. 9.
    Rumeau-Rouquette C, Goujard J, Huel G. Possible teratogenic effect of phenothiazines in human beings. Teratology 1977 Feb; 15(1): 57–64PubMedCrossRefGoogle Scholar
  10. 10.
    Slone D, Siskind V, Heinonen OP, et al. Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am J Obstet Gynecol 1977 Jul; 128(5): 486–8PubMedGoogle Scholar
  11. 11.
    Schou M, Goldfield MD, Weinstein MR, et al. Lithium and pregnancy: report from the Register of Lithium Babies. BMJ 1973 Apr; 2(5859): 135–6PubMedCrossRefGoogle Scholar
  12. 12.
    Kallen B, Tandberg A. Lithium and pregnancy: a cohort study on manic-depressive women. Acta Psychiatr Scand 1983 Aug; 68(2): 134–9PubMedCrossRefGoogle Scholar
  13. 13.
    Cohen LS, Friedman JM, Jefferson JW, et al. A reevaluation of risk of in utero exposure to lithium. JAMA 1994 Jan; 271(2): 146–50PubMedCrossRefGoogle Scholar
  14. 14.
    Shaw GM, Wasserman CR, O’Malley CD, et al. Orofacial clefts and maternal anticonvulsant use. Reprod Toxicol 1995 Jan-Feb; 9(1): 97–8PubMedCrossRefGoogle Scholar
  15. 15.
    Laegreid L, Olegard R, Conradi N, et al. Congenital malformations and maternal consumption of benzodiazepines: a case-control study. Dev Med Child Neurol 1990 May; 32(5): 432–41PubMedCrossRefGoogle Scholar
  16. 16.
    McKenna K, Koren G, Tetelbaum M, et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry 2005 Apr; 66(4): 444–9PubMedCrossRefGoogle Scholar
  17. 17.
    Fleischhacker W, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12 month evaluation of the first long-acting 2nd generation antipsychotic. J Clin Psychiatry 2003 Oct; 64: 1250–7PubMedCrossRefGoogle Scholar
  18. 18.
    Kane JM, Eerdekens M, Lindenmayer JP, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotics. Am J Psychiatry Jun 2003; 160(6): 1125–32PubMedCrossRefGoogle Scholar
  19. 19.
    Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 2005 Jan; 15(1): 111–7PubMedCrossRefGoogle Scholar
  20. 20.
    Hirschfeld RM, Keck PE Jr, Kramer M, et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry 2004 Jun; 161(6): 1057–65PubMedCrossRefGoogle Scholar
  21. 21.
    Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropharmacol 1998 May-Jun; 21(3): 176–180PubMedGoogle Scholar
  22. 22.
    Sachs GS, Grossman F, Ghaemi SN, et al. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry 2002 Jul; 159(7): 1146–54PubMedCrossRefGoogle Scholar
  23. 23.
    Data on file, Johnson & Johnson, 2006Google Scholar
  24. 24.
    Risperdal (risperidone). Janssen, LP prescribing information [online]. Available from URL: http://www.risperdal.com [Accessed 2005 Dec 1]Google Scholar
  25. 25.
    Reilly T, Heylen SLE. Guidelines for the practical use of risperidone. In: Kane JM, Moller HJ, Awouters F, editors. Serotonin in antipsychotic treatment. New York (NY): Dekker Inc, 1996: 357–68Google Scholar
  26. 26.
    Medical Economics staff, editors. Physicians’ Desk Reference. 57th ed. Montvale (NJ): Thomson PDR, 2003Google Scholar
  27. 27.
    March of Dimes [online]. Available from URL: http://www.marchofdimes.com [Accessed 2006 Jan 3]Google Scholar
  28. 28.
    American College of Obstetics and Gynecology [online]. Available from URL: http://www.americanpregnancy.org. [Accessed 2005 Dec 1]Google Scholar
  29. 29.
    Howard LM, Kumar R, Thornicroft G. Psychosocial characteristics and needs of mothers with psychotic disorders. Br J Psychiatry 2001 May; 178: 427–32PubMedCrossRefGoogle Scholar
  30. 30.
    Allison SK. Psychotropic medication in pregnancy: ethical aspects and clinical management. J Perinat Neonatal Nurs 2004 Jul-Sept; 18(3): 194–205PubMedGoogle Scholar
  31. 31.
    Casiano ME, Hawkins DR. Major mental illness and childbearing: a role for the consultation-liaison psychiatrist in obstetrics. Psychiatr Clin North Am 1987 Mar; 10(1): 35–51PubMedGoogle Scholar
  32. 32.
    Bagnall AM, Jones L, Ginnelly L, et al. A systematic review of atypical antipsychotic drugs in schizophrenia. Health Technol Assess 2003; 7(13): 1–193PubMedGoogle Scholar
  33. 33.
    Moller HJ. Neuroleptic treatment of negative symptoms in schizophrenic patients: efficacy problems and methodological difficulties. Eur Neuropsychopharmacol 1993 March; 3(1): 1–11PubMedCrossRefGoogle Scholar
  34. 34.
    Stanniland C, Taylor D. Tolerability of atypical antipsychotics. Drug Safety 2000 Mar; 22(3): 195–214PubMedCrossRefGoogle Scholar
  35. 35.
    Wolfgang P, Schloemp S, Sterzik K, et al. Atypical antipstychotic agents in early pregnancy. Reprod Toxicol 2005; 20: 453–91CrossRefGoogle Scholar
  36. 36.
    Maciag D, Simpson KL, Coppinger D, et al. Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry. Neuropsychopharmacology 2006 Jan; 31(1): 47–57PubMedGoogle Scholar
  37. 37.
    Costei AM, Kozer E, Ho T, et al. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002 Nov; 156(11): 1129–32PubMedCrossRefGoogle Scholar
  38. 38.
    Lin AE, Peller AJ, Westgate MN, et al. Clonazepam use in pregnancy and the risk of malformations. Birth Defects Res Clin Mol Teratol 2004 Dec; 70(8): 534–6CrossRefGoogle Scholar
  39. 39.
    Iqbal MM, Sobhan T, Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatr Serv 2002 Jan; 53(1): 39–49PubMedCrossRefGoogle Scholar
  40. 40.
    Pennell PB. Using current evidence in selecting antiepileptic drugs for use during pregnancy. Epilepsy Curr 2005 Mar-Apr; 5(2): 45–515 (2)PubMedCrossRefGoogle Scholar
  41. 41.
    Bennedsen BE. Adverse pregnancy outcome in schizophrenic women: occurrence and risk factors. Schizophr Res 1998 Sept; 33(1-2): 1–26PubMedCrossRefGoogle Scholar
  42. 42.
    Kallen K. Maternal smoking and urinary organ malformations. Int J Epidemiol 1997 Jun; 26(3): 571–4PubMedCrossRefGoogle Scholar
  43. 43.
    Meyer KA, Williams P, Hernandez-Diaz S, et al. Smoking and the risk of oral clefts: exploring the impact of study designs. Epidemiology 2004 Nov; 15(6): 671–8PubMedCrossRefGoogle Scholar
  44. 44.
    Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990 Nov; 264(19): 2511–8PubMedCrossRefGoogle Scholar
  45. 45.
    Singer HS. Tardive dyskinesia: a concern for the pediatrician. Pediatrics 1986 Apr; 77(4): 553–6PubMedGoogle Scholar
  46. 46.
    Gualtieri CT, Quade D, Hicks RE, et al. Tardive dyskinesia and other clinical consequences of neuroleptic treatment in children and adolescents. Am J Psychiatry 1984 Jan; 141(1): 20–3PubMedGoogle Scholar
  47. 47.
    Sexson WR, Barak Y. Withdrawal emergent syndrome in an infant associated with maternal haloperidol therapy. J Perinatol 1989 Jun; 9(2): 170–2PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  • Danielle Coppola
    • 1
  • Leo J. Russo
    • 1
  • Robert F. KwartaJr
    • 1
  • Ruana Varughese
    • 1
  • Juergen Schmider
    • 1
  1. 1.Benefit Risk Management, a division of Johnson & Johnson Pharmaceutical Research & DevelopmentTitusvilleUSA

Personalised recommendations